← Back

Shanghai Haohai Biological Tech Co

Shanghai Haohai Biological Technology Co., Ltd. researches, develops, manufactures, and sells biomedical materials in Mainland China, Europe, the United States, and internationally. Its products include ophthalmic implants, medical devices, intraocular lenses, endoscopic equipment, ophthalmic surgical instruments, hyaluronic acid, chitosan, and electronic instruments such as semiconductors, lasers, and ultrasonic devices. The company also develops biological engineering and pharmaceutical products, provides technology transfer and consulting services, and manufactures biological reagents and medical-grade skincare products. Founded in 2007 and headquartered in Shanghai, it was formerly known as Haohai Limited and changed its name in 2010.

Country
Price · split & dividend adjusted
News & notes moving 688366.CG
688366.CG▼2

Haohai Biological Technology's 2026 interim report shows net profit of 113 million yuan, down 46.64% year-on-year

Haohai Biological Technology released its 2026 interim report, with net profit attributable to the parent company of 113 million yuan, a decrease of 46.64% compared with the same period last year. The company's total operating revenue was 1.179 billion yuan, down 9.60% year-on-year; net cash inflow from operating activities was 128 million yuan, down 57.77% year-on-year. The company's latest gross margin was 65.46%, a decrease of 4.70 percentage points from the same period last year; the latest return on equity was 2.12%, a decrease of 1.64 percentage points from the same period last year. Diluted earnings per share were 0.49 yuan, down 46.15% year-on-year.
688366.CG ▼
Jiemian·26dRead more →
688366.CG▲

Haohai Biological Technology Plans Dividend of 2.5 Yuan per 10 Shares

Haohai Biological Technology announced plans to distribute a cash dividend of 2.5 yuan, tax included, for every 10 shares held by all shareholders. The total payout is expected to be 56.19 million yuan, accounting for 49.89 percent of net profit attributable to the parent company. In the first half of 2026, the company achieved revenue of 1.179 billion yuan and net profit attributable to the parent company of 113 million yuan.
688366.CG ▲
财中社·29dRead more →
688366.CG▲2

Haohai Biological Technology Subsidiary Receives Medical Device Registration Certificate for Trifocal Toric Intraocular Lens

Haohai Biological Technology's controlled subsidiary, Henan Saimeishi Biotechnology Co., Ltd., has obtained the Medical Device Registration Certificate of the People's Republic of China from the National Medical Products Administration for its trifocal toric intraocular lens. The product is indicated for vision correction in adult cataract patients with corneal astigmatism who have no natural lens, aiming to correct corneal astigmatism while improving near, intermediate, and distance vision and reducing dependence on glasses. In the first quarter of 2026, Haohai Biological Technology achieved revenue of 571 million yuan and net profit attributable to the parent company of 73.56 million yuan.
688366.CG ▲
财中社·44dRead more →
© 2026 MarketDXAsset